Vlad Coric, MD

Vlad Coric, MD serves as Chief Executive Officer and as a director of Biohaven (NYSE: BHVN). He has been involved in multiple drug development programs, including marketed drugs or filed NDAs such as Nurtec® ODT (rimegepant; oral calcitonin related peptide antagonist), Zavzpret® (zavegepant; intranasal calcitonin related peptide antagonist), Abilify® (aripiprazole; partial dopamine agonist), Opdivo® (nivolumab; anti-PD1), Yervoy® (Ipilimumab; anti-CTLA-4), Daklinza® (daclatasvir; NS5A inhibitor) and Sunvepra® (asunaprevir; NS3 inhibitor). From January 2007 to September 2015, he served as a group director of global clinical research at Bristol-Myers Squibb Company focusing both in oncology global clinical research and neuroscience global clinical research. Since 2006, Vlad has also served as an associate clinical professor of psychiatry at Yale School of Medicine. Vlad completed his postdoctoral internship, residency and fellowship at Yale School of Medicine, received his MD from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut where he received a BS degree.